Abstract
Background: Cyclin B2 (CCNB2) is an important component of the cyclin pathway and plays a key role in the occurrence and development of cancer. However, the correlation between prognosis of low-grade glioma (LGG), CCNB2, and tumor infiltrating lymphocytes is not clear. Methods: The expression of CCNB2 in LGG was queried in Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and TIMER databases. The relationships between CCNB2 and the clinicopathological features of LGG were analyzed using the Chinese Glioma Genome Atlas (CGGA) database. The relationship between CCNB2 expression and overall survival (OS) was evaluated by GEPIA2. The correlation between CCNB2 and LGG immune infiltration was analyzed by the TIMER database. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect CCNB2 expression. Results: The expression of CCNB2 differed across different tumor tissues, but was higher in LGG than in normal tissues. LGG patients with high expression of CCNB2 have poorer prognosis. The expression of CCNB2 was correlated with age, WHO grade, IDH mutational status, 1p/19q codeletion status, and other clinicopathological features. The expression of CCNB2 in LGG was positively correlated with the infiltration level of B cells, dendritic cells, and macrophages. qRT-PCR results revealed that the expression of CCNB2 in LGG tissues was higher than normal tissues and higher expression of CCNB2 was associated with worse prognosis. Conclusion: CCNB2 may be used as a potential biomarker to determine the prognosis of LGG and is also related to immune infiltration.
Highlights
Low-grade glioma (LGG) is a common primary malignant tumor, which accounts for ∼20% of primary brain tumors [1]
The abnormal expression of CCND1 and CCNE1 promotes the proliferation of lung adenocarcinoma, the down-regulation of cyclin A2 affects the proliferation of colon cancer cells [6]; cyclin A2 is highly expressed in thyroid cancer [7]
The results of Cyclin B2 (CCNB2) and expression in various cancers showed that compared with the normal tissues, the expression of CCNB2 increased in BLCA, BRCA, OV, GBM, UCEC and many other cancers, but only decreased in LAML (Figure 1A)
Summary
Low-grade glioma (LGG) is a common primary malignant tumor, which accounts for ∼20% of primary brain tumors [1]. Cyclin (CCN) family members are the key regulators of cell cycle progression and play a regulatory role in different stages of the cell cycle. Their abnormal expression often leads to tumorigenesis. The abnormal expression of CCND1 and CCNE1 promotes the proliferation of lung adenocarcinoma, the down-regulation of cyclin A2 affects the proliferation of colon cancer cells [6]; cyclin A2 is highly expressed in thyroid cancer [7]. The correlation between prognosis of low-grade glioma (LGG), CCNB2, and tumor infiltrating lymphocytes is not clear. The correlation between CCNB2 and LGG immune infiltration was analyzed by the TIMER database. Conclusion: CCNB2 may be used as a potential biomarker to determine the prognosis of LGG and is related to immune infiltration
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
